Our Specialists

Khin Maung U, Tin A, Ku Tin M, Tin O, Myo K, Thackway SA, Connor SJ, Bolin TD, Duncombe VM. In vitro hydrogen production by enteric bacteria cultured from children with small bowel bacterial overgrowth. J Pediatr Gastroenterol Nutr. 1992;14(2):192-197. doi: 10.1097/00005176-199202000-00013

Norrie MW, Chapman G, Connor SJ. A case of upper gastrointestinal bleeding secondary to a bread bag clip. Aust N Z J Med. 1997;27(1):75. doi: 10.1111/j.1445-5994.1997.tb00918.x

Connor SJ, Ngu MC, Katelaris PH. The impact of short-term ranitidine use on the precision of the 13C-urea breath test in subjects infected with Helicobacter pylori. Eur J Gastroenterol Hepatol. 1999;11(10):1135-1138. doi: 10.1097/00042737-199910000-00010

Connor SJ, Seow F, Ngu MC, Katelaris PH. The effect of dosing with omeprazole on the accuracy of the 13C-urea breath test in Helicobacter pylori-infected subjects. Aliment Pharmacol Ther. 1999;13(10):1287-1293. doi: 10.1046/j.1365-2036.1999.00601.x

Connor SJ, Grimm MC. Heparin as an anti-inflammatory agent: it's no GAG to forget about chemokines. Gut. 2001;48(5):738. doi: 10.1136/gut.48.5.738

Grimm MC, Newman R, Hassim Z, Cuan N, Connor SJ, Le Y, Wang JM, Oppenheim JJ, Lloyd AR. Cutting edge: vasoactive intestinal peptide acts as a potent suppressor of inflammation in vivo by trans-deactivating chemokine receptors. J Immunol. 2003;171(10):4990-4994. doi: 10.4049/jimmunol.171.10.4990

Connor SJ, Paraskevopoulos N, Newman R, Cuan N, Hampartzoumian T, Lloyd AR, Grimm MC. CCR2 expressing CD4+ T lymphocytes are preferentially recruited to the ileum in Crohn's disease. Gut. 2004;53(9):1287-1294. doi: 10.1136/gut.2003.028225

Newman R, Cuan N, Hampartzoumian T, Connor SJ, Lloyd AR, Grimm MC. Vasoactive intestinal peptide impairs leucocyte migration but fails to modify experimental murine colitis. Clin Exp Immunol. 2005;139(3):411-420. doi: 10.1111/j.1365-2249.2005.02673.x

Chin BW, Grimm MC, Connor SJ, Leong RW. Managing inflammatory bowel disease. Medicine Today. 2006;7:14-24.

Koo JH, Jalaludin B, Wong SK, Kneebone A, Connor SJ, Leong RW. Improved survival in young women with colorectal cancer. Am J Gastroenterol. 2008;103(6):1488-1495. doi: 10.1111/j.1572-0241.2007.01779.x

Koo JH, Kin S, Wong C, Jalaludin B, Kneebone A, Connor SJ, Leong RW. Clinical and pathologic outcomes of colorectal cancer in a multi-ethnic population. Clin Gastroenterol Hepatol. 2008;6(9):1016-1021. doi: 10.1016/j.cgh.2008.03.018

Koo JH, Arasaratnam MM, Liu K, Redmond DM, Connor SJ, Sung JJ, Leong RW. Knowledge, perception and practices of colorectal cancer screening in an ethnically diverse population. Cancer Epidemiol. 2010;34(5):604-610. doi: 10.1016/j.canep.2010.05.013

Ellard KT, Connor SJ. Inflammatory Bowel Disease: How To Treat. Australian Doctor. 2011:29-34.

Fok KC, Ng WW, Henderson CJ, Connor SJ. Cutaneous sarcoidosis in a patient with ulcerative colitis on infliximab. J Crohns Colitis. 2012;6(6):708-712. doi: 10.1016/j.crohns.2012.01.008

Koo JH, You MY, Liu K, Athureliya MD, Tang CW, Redmond DM, Connor SJ, Leong RW. Colorectal cancer screening practise is influenced by ethnicity of medical practitioner and patient. J Gastroenterol Hepatol. 2012;27(2):390-396. doi: 10.1111/j.1440-1746.2011.06872.x

Walsh AJ, Weltman M, Burger D, Vivekanandarajah S, Connor S, Howlett M, Radford-Smith G, Selby W, Veillard AS, Grimm MC, Travis SP, Lawrance IC. Implementing guidelines on the prevention of opportunistic infections in inflammatory bowel disease. J Crohns Colitis. 2013;7(10):e449-456. doi: 10.1016/j.crohns.2013.02.019

Heap GA, Weedon MN, Bewshea CM, Singh A, Chen M, Satchwell JB, Vivian JP, So K, Dubois PC, Andrews JM, Annese V, Bampton P, Barnardo M, Bell S, Cole A, Connor SJ, Creed T, Cummings FR, D'Amato M, Daneshmend TK, Fedorak RN, Florin TH, Gaya DR, Greig E, Halfvarson J, Hart A, Irving PM, Jones G, Karban A, Lawrance IC, Lee JC, Lees C, Lev-Tzion R, Lindsay JO, Mansfield J, Mawdsley J, Mazhar Z, Parkes M, Parnell K, Orchard TR, Radford-Smith G, Russell RK, Reffitt D, Satsangi J, Silverberg MS, Sturniolo GC, Tremelling M, Tsianos EV, van Heel DA, Walsh A, Watermeyer G, Weersma RK, Zeissig S, Rossjohn J, Holden AL, International Serious Adverse Events C, Group IBDPS, Ahmad T. HLA-DQA1-HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants. Nat Genet. 2014;46(10):1131-1134. doi: 10.1038/ng.3093

Hussain MI, Hall BM, Depczynski B, Connor SJ. Acute renal failure and metformin-associated lactic acidosis following colonoscopy. Diabetes Res Clin Pract. 2014;105(1):e6-8. doi: 10.1016/j.diabres.2013.12.055

Ko Y, Karnib M, Samuels D, Alrubaie A, Rahme N, McDonald C, Katelaris P, Barr G, Jones B, Paven G, Chapman G, Park G, Meredith C, Connor S, Gearry R, Leong RW. Environmental Risk Factors for Inflammatory Bowel Disease: A Case-Control Study in a Middle Eastern Migrant Population. Clin Gastroenterol Hepatol. 2014;12(1):160-161. doi: 10.1016/j.cgh.2013.09.041

Costello SP, Ghaly S, Beswick L, Pudipeddi A, Agarwal A, Sechi A, O’Connor S, Connor SJ, Sparrow MP, Bampton P, Walsh AJ, Andrews JM, Australian Inflammatory Bowel Disease A. Compassionate access anti-tumour necrosis factor-alpha therapy for ulcerative colitis in Australia: the benefits to patients. Intern Med J. 2015;45(6):659-666. doi: 10.1111/imj.12732

Ghaly S, Costello S, Beswick L, Pudipeddi A, Agarwal A, Sechi A, Antoniades S, Headon B, Connor S, Lawrance IC, Sparrow M, Walsh AJ, Andrews JM, Aibda. Dose tailoring of anti-tumour necrosis factor-alpha therapy delivers useful clinical efficacy in Crohn disease patients experiencing loss of response. Intern Med J. 2015;45(2):170-177. doi: 10.1111/imj.12621

Ko Y, Kariyawasam V, Karnib M, Butcher R, Samuel D, Alrubaie A, Rahme N, McDonald C, Cowlishaw J, Katelaris P, Barr G, Jones B, Connor S, Paven G, Chapman G, Park G, Gearry R, Leong RW, Organisation IBDS. Inflammatory Bowel Disease Environmental Risk Factors: A Population-Based Case-Control Study of Middle Eastern Migration to Australia. Clin Gastroenterol Hepatol. 2015;13(8):1453-1463 e1451. doi: 10.1016/j.cgh.2015.02.045

Paramsothy S, Borody TJ, Lin E, Finlayson S, Walsh AJ, Samuel D, van den Bogaerde J, Leong RW, Connor S, Ng W, Mitchell HM, Kaakoush N, Kamm MA. Donor Recruitment for Fecal Microbiota Transplantation. Inflamm Bowel Dis. 2015;21(7):1600-1606. doi: 10.1097/MIB.0000000000000405

Paramsothy S, Walsh AJ, Borody T, Samuel D, van den Bogaerde J, Leong RW, Connor S, Ng W, Mitchell HM, Kaakoush NO, Kamm MA. Gastroenterologist perceptions of faecal microbiota transplantation. World J Gastroenterol. 2015;21(38):10907-10914. doi: 10.3748/wjg.v21.i38.10907

Andrews JM, Costello SP, Agarwal AK, Bampton P, Beswick L, Connor S, Ghaly S, O’Connor S, Pudipeddi A, Sechi A, Sparrow M, Walsh AJ. Conflict of interest: real and perceived--a more mature consideration is needed. Intern Med J. 2016;46(3):377-379. doi: 10.1111/imj.12989

Chen JH, Andrews JM, Kariyawasam V, Moran N, Gounder P, Collins G, Walsh AJ, Connor S, Lee TW, Koh CE, Chang J, Paramsothy S, Tattersall S, Lemberg DA, Radford-Smith G, Lawrance IC, McLachlan A, Moore GT, Corte C, Katelaris P, Leong RW, Organisation IBDS, the Australian Inflammatory Bowel Diseases Consensus Working G. Review article: acute severe ulcerative colitis - evidence-based consensus statements. Aliment Pharmacol Ther. 2016;44(2):127-144. doi: 10.1111/apt.13670

Elnawsra O, Fok I, Sparrow M, Gibson P, Andrews J, Connor S. Faecal calprotectin: current usage and perceived beneficial effects of third-party funding on rates of colonoscopy by Australian gastroenterologists. Intern Med J. 2016;46(5):590-595. doi: 10.1111/imj.13056

Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR, Blank MA, Johanns J, Gao LL, Miao Y, Adedokun OJ, Sands BE, Hanauer SB, Vermeire S, Targan S, Ghosh S, de Villiers WJ, Colombel JF, Tulassay Z, Seidler U, Salzberg BA, Desreumaux P, Lee SD, Loftus EV, Jr., Dieleman LA, Katz S, Rutgeerts P, Group U-I-US. Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease. N Engl J Med. 2016;375(20):1946-1960. doi: 10.1056/NEJMoa1602773

Julsgaard M, Christensen LA, Gibson PR, Gearry RB, Fallingborg J, Hvas CL, Bibby BM, Uldbjerg N, Connell WR, Rosella O, Grosen A, Brown SJ, Kjeldsen J, Wildt S, Svenningsen L, Sparrow MP, Walsh A, Connor SJ, Radford-Smith G, Lawrance IC, Andrews JM, Ellard K, Bell SJ. Concentrations of Adalimumab and Infliximab in Mothers and Newborns, and Effects on Infection. Gastroenterology. 2016;151(1):110-119. doi: 10.1053/j.gastro.2016.04.002

Lee MW, Connor S, Ng W, Toong CM. Comparison of infliximab drug measurement across three commercially available ELISA kits. Pathology. 2016;48(6):608-612. doi: 10.1016/j.pathol.2016.07.001

Connor SJ. Biologic Therapeutic Drug Monitoring in Australia. J Gastroenterol Hepatol. 2016;31 Suppl 1:8-9. doi: 10.1111/jgh.13346

Stein J, Connor SJ, Virgin G, Ong DE, Pereyra L. Anemia and iron deficiency in gastrointestinal and liver conditions. World J Gastroenterol. 2016;22(35):7908-7925. doi: 10.3748/wjg.v22.i35.7908

Thompson KD, Connor SJ, Walls DM, Gollins J, Stewart SK, Bewtra M, Baumblatt GL, Holubar SD, Greenup AJ, Sechi A, Girgis A, Rubin DT, Siegel CA. Patients with Ulcerative Colitis Are More Concerned About Complications of Their Disease than Side Effects of Medications. Inflamm Bowel Dis. 2016;22(4):940-947. doi: 10.1097/mib.0000000000000740

Aggarwal V, Day AS, Connor SJ, Leach ST, Brown G, Singh R, Friedman A, Zekry A, Craig PI. Role of capsule endoscopy and fecal biomarkers in small-bowel Crohn's disease to assess remission and predict relapse. Gastrointest Endosc. 2017;86(6):1070-1078. doi: 10.1016/j.gie.2017.09.011

Bye WA, Sparrow MP, Connor SJ, Andrews JM, Ellard K, Ng W, Hume G, Antoniades S, Walsh AJ. The need for better preventative strategies for inflammatory bowel disease patients at risk of herpes zoster virus. Intern Med J. 2017;47(11):1263-1269. doi: 10.1111/imj.13488

Chen GB, Lee SH, Montgomery GW, Wray NR, Visscher PM, Gearry RB, Lawrance IC, Andrews JM, Bampton P, Mahy G, Bell S, Walsh A, Connor S, Sparrow M, Bowdler LM, Simms LA, Krishnaprasad K, International IBDGC, Radford-Smith GL, Moser G. Performance of risk prediction for inflammatory bowel disease based on genotyping platform and genomic risk score method. BMC Med Genet. 2017;18(1):94. doi: 10.1186/s12881-017-0451-2

Doecke JD, Hartnell F, Bampton P, Bell S, Mahy G, Grover Z, Lewindon P, Jones LV, Sewell K, Krishnaprasad K, Prosser R, Marr D, Fischer J, G RT, Tehan JV, Ding NS, Cooke SE, Moss K, Sechi A, De Cruz P, Grafton R, Connor SJ, Lawrance IC, Gearry RB, Andrews JM, Radford-Smith GL, Australian, New Zealand Inflammatory Bowel Disease C. Infliximab vs. adalimumab in Crohn's disease: results from 327 patients in an Australian and New Zealand observational cohort study. Aliment Pharmacol Ther. 2017;45(4):542-552. doi: 10.1111/apt.13880

Lawrance IC, Baird A, Lightower D, Radford-Smith G, Andrews JM, Connor S. Efficacy of Rectal Tacrolimus for Induction Therapy in Patients With Resistant Ulcerative Proctitis. Clin Gastroenterol Hepatol. 2017;15(8):1248-1255. doi: 10.1016/j.cgh.2017.02.027

Mitrev N, Vande Casteele N, Seow CH, Andrews JM, Connor SJ, Moore GT, Barclay M, Begun J, Bryant R, Chan W, Corte C, Ghaly S, Lemberg DA, Kariyawasam V, Lewindon P, Martin J, Mountifield R, Radford-Smith G, Slobodian P, Sparrow M, Toong C, van Langenberg D, Ward MG, Leong RW, Organisation IBDS, the Australian Inflammatory Bowel Diseases Consensus Working G. Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases. Aliment Pharmacol Ther. 2017;46(11-12):1037-1053. doi: 10.1111/apt.14368

Paramsothy S, Kamm MA, Kaakoush NO, Walsh AJ, van den Bogaerde J, Samuel D, Leong RWL, Connor S, Ng W, Paramsothy R, Xuan W, Lin E, Mitchell HM, Borody TJ. Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial. Lancet. 2017;389(10075):1218-1228. doi: 10.1016/S0140-6736(17)30182-4

Toong CM, Lee MW, Connor S, Ng W. Response to: Comparison of infliximab drug measurement across three commercially available ELISA kits: author reply. Pathology. 2017;49(3):334-335. doi: 10.1016/j.pathol.2017.01.005

Connor S. What can Australian Inflammatory Bowel Disease Association achieve in the next 3 to 5 years? J Gastroenterol Hepatol. 2018;33 Suppl 3:35. doi: 10.1111/jgh.14437

Liu F, Ma R, Tay CYA, Octavia S, Lan R, Chung HKL, Riordan SM, Grimm MC, Leong RW, Tanaka MM, Connor S, Zhang L. Genomic analysis of oral Campylobacter concisus strains identified a potential bacterial molecular marker associated with active Crohn's disease. Emerg Microbes Infect. 2018;7(1):64. doi: 10.1038/s41426-018-0065-6

An YK, Prince D, Gardiner F, Neeman T, Linedale EC, Andrews JM, Connor S, Begun J. Faecal calprotectin testing for identifying patients with organic gastrointestinal disease: systematic review and meta-analysis. Med J Aust. 2019;211(10):461-467. doi: 10.5694/mja2.50384

Little RD, Chu IE, van der Zanden EP, Flanagan E, Bell SJ, Gibson PR, Sparrow MP, Shelton E, Connor SJ, Roblin X, Ward MG. Comparison of Adalimumab Serum Drug Levels When Delivered by Pen Versus Syringe in Patients With Inflammatory Bowel Disease. An International, Multicentre Cohort Analysis. J Crohns Colitis. 2019;13(12):1527-1536. doi: 10.1093/ecco-jcc/jjz103

Paramsothy S, Nielsen S, Kamm MA, Deshpande NP, Faith JJ, Clemente JC, Paramsothy R, Walsh AJ, van den Bogaerde J, Samuel D, Leong RWL, Connor SJ, Ng W, Lin E, Borody TJ, Wilkins MR, Colombel JF, Mitchell HM, Kaakoush NO. Specific Bacteria and Metabolites Associated With Response to Fecal Microbiota Transplantation in Patients With Ulcerative Colitis. Gastroenterology. 2019;156(5):1440-1454 e1442. doi: 10.1053/j.gastro.2018.12.001

Walker GJ, Harrison JW, Heap GA, Voskuil MD, Andersen V, Anderson CA, Ananthakrishnan AN, Barrett JC, Beaugerie L, Bewshea CM, Cole AT, Cummings FR, Daly MJ, Ellul P, Fedorak RN, Festen EAM, Florin TH, Gaya DR, Halfvarson J, Hart AL, Heerasing NM, Hendy P, Irving PM, Jones SE, Koskela J, Lindsay JO, Mansfield JC, McGovern D, Parkes M, Pollok RCG, Ramakrishnan S, Rampton DS, Rivas MA, Russell RK, Schultz M, Sebastian S, Seksik P, Singh A, So K, Sokol H, Subramaniam K, Todd A, Annese V, Weersma RK, Xavier R, Ward R, Weedon MN, Goodhand JR, Kennedy NA, Ahmad T, Group IBDPS. Association of Genetic Variants in NUDT15 With Thiopurine-Induced Myelosuppression in Patients With Inflammatory Bowel Disease. JAMA. 2019;321(8):773-785. doi: 10.1001/jama.2019.0709

Aysha AA, Rentsch C, Prentice R, Johnson D, Bryant RV, Ward MG, Costello SP, Lewindon P, Ghaly S, Connor SJ, Begun J, Christensen B. Practical management of inflammatory bowel disease patients during the COVID-19 pandemic: expert commentary from the Gastroenterological Society of Australia Inflammatory Bowel Disease faculty. Intern Med J. 2020;50(7):798-804. doi: 10.1111/imj.14889

Benson MJ, Abelev SV, Connor SJ, Corte CJ, Martin LJ, Gold LK, Suraev AS, McGregor IS. Medicinal Cannabis for Inflammatory Bowel Disease: A Survey of Perspectives, Experiences, and Current Use in Australian Patients. Crohns & Colitis 360. 2020; 2(2). doi:10.1093/crocol/otaa015.
19th most talked about journal article in gastroenterology in 2021 

Benson MJ, Abelev SV, Corte CJ, Connor SJ, McGregor IS. Attitudes and Knowledge of Australian Gastroenterologists Around the Use of Medicinal Cannabis for Inflammatory Bowel Disease. Crohns & Colitis 360. 2020; 2(2). doi:10.1093/crocol/otaa045

Flanagan E, Gibson PR, Wright EK, Moore GT, Sparrow MP, Connell W, Kamm MA, Begun J, Christensen B, De Cruz P, Shelton E, Dowling D, Andrews JM, Brown SJ, Niewiadomski O, Ward MG, Rosella O, Rosella G, Kiburg KV, Ross AL, Bell SJ, Group PS. Infliximab, adalimumab and vedolizumab concentrations across pregnancy and vedolizumab concentrations in infants following intrauterine exposure. Aliment Pharmacol Ther. 2020;52(10):1551-1562. doi: 10.1111/apt.16102

Gardiner FW, Bishop L, McMahon K, Nwose EU, Connor SJ, Begun J, Andrews JM. Aeromedical retrievals for gastrointestinal disorders in rural and remote Australia: the need for improved access to specialist advice. Intern Med J. 2020;50(5):619-623. doi: 10.1111/imj.14822

Haifer C, Kelly CR, Paramsothy S, Andresen D, Papanicolas LE, McKew GL, Borody TJ, Kamm M, Costello SP, Andrews JM, Begun J, Chan HT, Connor SJ, Ghaly S, Johnson PD, Lemberg DA, Paramsothy R, Redmond A, Sheorey H, van der Poorten D, Leong RW. Australian consensus statements for the regulation, production and use of faecal microbiota transplantation in clinical practice. Gut. 2020;69(5):801-810. doi: 10.1136/gutjnl-2019-320260

Julsgaard M, Hvas CL, Gearry RB, Gibson PR, Fallingborg J, Sparrow MP, Bibby BM, Connell WR, Brown SJ, Kamm MA, Lawrance IC, Vestergaard T, Svenningsen L, Baekdal M, Kammerlander H, Walsh A, Boysen T, Bampton P, Radford-Smith G, Kjeldsen J, Andrews JM, Subramaniam K, Moore GT, Jensen NM, Connor SJ, Wildt S, Wilson B, Ellard K, Christensen LA, Bell SJ. Anti-TNF Therapy in Pregnant Women With Inflammatory Bowel Disease: Effects of Therapeutic Strategies on Disease Behavior and Birth Outcomes. Inflamm Bowel Dis. 2020;26(1):93-102. doi: 10.1093/ibd/izz110

Karimi N, Moore AR, Lukin A, Kanazaki R, Williams AJ, Connor SJ. Clinical communication in inflammatory bowel disease: a systematic literature review protocol. BMJ Open. 2020;10(11):e039503. 10.1136/bmjopen-2020-039503

Kim AH, Girgis A, Karimi N, Sechi AJ, Descallar J, Andrews JM, Siegel CA, Connor SJ. A Web-Based Decision Aid (myAID) to Enhance Quality of Life, Empowerment, Decision Making, and Disease Control for Patients With Ulcerative Colitis: Protocol for a Cluster Randomized Controlled Trial. JMIR Res Protoc. 2020;9(7):e15994. doi: 10.2196/15994

Krishnaprasad K, Walsh A, Begun J, Bell S, Carter D, Grafton R, Sechi A, Sewell K, McMahon A, Connor SJ, Radford-Smith G, Andrews JM. Australia and New Zealand Inflammatory Bowel Disease Consortium and Crohn's Colitis Cure. Crohn's Colitis Care (CCCare): bespoke cloud-based clinical management software for inflammatory bowel disease. Scand J Gastroenterol. 2020;55(12):1419-1426. doi: 10.1080/00365521.2020.1839960

Pulusu SSR, Srinivasan A, Krishnaprasad K, Cheng D, Begun J, Keung C, Van Langenberg D, Thin L, Mogilevski T, De Cruz P, Radford-Smith G, Flanagan E, Bell S, Kashkooli S, Sparrow M, Ghaly S, Bampton P, Sawyer E, Connor SJ, Rizvi QU, Andrews JM, Mahy G, Chivers P, Travis S, Lawrance IC. Vedolizumab for ulcerative colitis: Real world outcomes from a multicenter observational cohort of Australia and Oxford. World J Gastroenterol. 2020; 26(30):4428-4441. doi: 10.3748/wjg.v26.i30.4428

Sam MJ, Connor SJ, Ng WW, Toong CM. Comparative Evaluation of 4 Commercially Available ELISA Kits for Measuring Adalimumab and Anti-adalimumab Antibodies. Ther Drug Monit. 2020; 42(6):821-828. doi: 10.1097/FTD.0000000000000795

Dubinsky MC, Watanabe K, Molander P, Peyrin-Biroulet L, Rubin M, Melmed GY, Deuring JJ, Woolcott J, Cappelleri JC, Steinberg K, Connor SJ. Ulcerative Colitis Narrative Global Survey Findings: The Impact of Living With Ulcerative Colitis-Patients' and Physicians' View. Inflamm Bowel Dis. 2021; 27: 1747–1755. doi: 10.1093/ibd/izab016

Gu B, De Gregorio M, Pipicella JL, Vande Casteele N, Andrews JM, Begun J, Connell W, D'Souza B, Gholamrezaei A, Hart A, Liew D, Radford-Smith G, Rimola J, Sutherland T, Toong C, Woods R, Wu Y, Xuan W, Williams AJ, Ng W, Ding NS, Connor SJ. Prospective randomised controlled trial of adults with perianal fistulising Crohn's disease and optimised therapeutic infliximab levels: PROACTIVE trial study protocol. BMJ Open. 2021;11(7):e043921. doi: 10.1136/bmjopen-2020-043921

Kanazaki R, Smith B, Girgis A, Descallar J, Connor SJ. Survey of barriers to adherence to international inflammatory bowel disease guidelines: Does gastroenterologists' confidence translate to high adherence? Intern Med J. 2021. doi:10.1111/imj.15299.

Karimi N, Sechi AJ, Harb M, Sawyer E, Williams AJ, Ng W, Connor SJ. The Effect of a Nurse-Led Advice-Line and Virtual Clinic on Inflammatory Bowel Disease Service Delivery: An Australian Study. Eur J Gastroenterol Hepatol. 2021; doi:10.1097/MEG.0000000000002249

Kim AH, Girgis A, De Cruz P, Siegel CA, Karimi N, Ruban SO, Sechi AJ, Ng WSW, Andrews JM, Connor SJ. Development and Feasibility of a Web-Based Decision Aid for Patients With Ulcerative Colitis: Qualitative Pilot Study. J Med Internet Res. 2021; 23(2):e15946. doi: 10.2196/15946

Mohsen W, Williams AJ, Wark G, Sechi A, Koo JH, Xuan W, Bassan M, Ng W, Connor SJ. Prospective single-blinded single-center randomized controlled trial of Prep Kit-C and Moviprep: Does underlying inflammatory bowel disease impact tolerability and efficacy? World J Gastroenterol. 2021; 27(11):1090-1100. doi: 10.3748/wjg.v27.i11.1090

Prentice RE, Rentsch C, Al-Ani AH, Zhang E, Johnson D, Halliday J, Bryant R, Begun J, Ward MG, Lewinden PJ, Connor SJ, Ghaly S, Christensen B. Review Article: SARS-CoV-2 Vaccination in Patients with Inflammatory Bowel Disease. GastroHep. 2021; 3(4):212-228. doi: 10.1002/ygh2.473

Williams AJ, Karimi N, Chari R, Connor SJ, De Vera MA, Dieleman LA, Hansen T, Ismond K, Khurana R, Kingston D, O’Connor K, Sadowski DC, Fang-Hwa F, Wine E, Leung Y, Huang V. Shared Decision Making in Pregnancy in Inflammatory Bowel Disease: Design of a Patient Orientated Decision Aid. BMC Gastroenterol. 2021; 21:302. doi: 10.1186/s12876-021-01853-y.

Williams AJ, Paramsothy R, Wu N, Ghaly S, Leach S, Paramsothy S, Corte C, O'Brien C, Burke C, Wark G, Samocha-Bonet D, Lambert K, Ahlenstiel G, Wasinger V, Dutt S, Pavli P, Grimm M, Lemberg D, Connor SJ, Leong R, Hold G. Australia IBD Microbiome (AIM) Study: protocol for a multicentre longitudinal prospective cohort study. BMJ Open. 2021; 11(2):e042493. doi: 10.1136/bmjopen-2020-042493

Wu Y, Lin B, Thilakanathan C, Lehmann P, Xuan W, Mohsen W, Toong C, Williams AJ, Ng W, Connor SJ. Therapeutic drug monitoring in inflammatory bowel disease reduces unnecessary use of infliximab with substantial associated cost-savings. Intern Med J. 2021; 51(5):739-745. doi: 10.1111/imj.14644

Wu Y, Wen A, Selvanderan SP, Xuan W, Andrews JM, Koo JH, Williams AJ, Ng W, Connor SJ. Management decisions in Crohn’s Disease are changed by knowledge of proactive and reactive testing of anti-tumour necrosis factor drug levels. Crohns Colitis 360. 2021; 3(3). doi: 10.1093/crocol/otab042.

Karimi K, Kanazaki R, Lukin A, Moore AR, Williams AJ, Connor SJ. Clinical communication in inflammatory bowel disease: a systematic review of the study of clinician-patient dialogue to inform research and practice. BMJ Open. 2021:11(8):e051053. doi: 10.1136/bmjopen-2021-051053

Connor SJ, Sechi A, Andrade M, Deuring JJ, Witcombe D. Ulcerative Colitis Narrative findings: Australian survey data comparing patient and physician disease management views. JGH Open. 2021; 5(9):1033-1040. doi: 10.1002/jgh3.12627

Kaazan P, Li T, Seow W, Bednarz J, Pipicella JL, Krishnaprasad K, Ng W, Williams AJ, Connor SJ, Andrews JM. Assessing effectiveness and patient perceptions of a novel electronic medical record for the management of inflammatory bowel disease. JGH Open. 2021; 5(9): 1063–1070. doi:10.1002/jgh3.12631

Crane H, Wu N, Chan P, Nguyen P, Williams AJ, Ng W, Connor SJ, Safety, satisfaction, and cost savings of accelerated infusions of standard and intensified-dose infliximab for inflammatory bowel disease. Intern Med J. 2021. doi: 10.1111/imj.15493

De Gregorio M, Lee T, Krishnaprasad K, Amos G, An YK, Bastian-Jordan M, Begun J, Borok N, Brown DJM, Cheung W, Connor SJ, Gerstenmaier J, Gilbert LE, Gilmore R, Gu B, Kutaiba N, Lee A, Mahy G, Srinivasan A, Thin L, Thompson AJ, Welman CJ, Yong EXZ, De Cruz P, van Langenberg D, Sparrow MP, Ding NS. Higher anti-tumour necrosis factor-α levels correlate with improved radiological outcomes in Crohn’s perianal fistulas. Clin Gastroenterol Hepatol. 2021. doi: 10.1016/j.cgh.2021.07.053

Kayes T, Bonnichsen M, Willmann L, Lorenzo A, Das A, El-Haddad C, Househ Z, Ng W, Ng W, Williams AJ, Prince D, Connor SJ. Menetrier’s disease exacerbating ulcerative colitis and relieved by gastrectomy. BMJ Open Gastroenterology. 2021; 8(1). doi: 10.1136/bmjgast-2021-000806

Harb M, Prince DS, Bassan M, Mackenzie S, Connor SJ, Rutland T. Extra-mammary Paget’s Disease Arising from a Non-invasive Rectal Adenoma. Pathology. 2022. doi:10.1016/j.pathol.2021.11.011.

Wang G, Karimi K, Willmann L, Descallar J, O’Connor K, Pipicella J, Connor SJ, Yvette Leung Y, Huang V, Williams AJ, A Novel Decision Aid Improves Quality of Reproductive Decision-Making and Pregnancy Knowledge for Women with Inflammatory Bowel Disease. Dig Dis Sci. 30 April 2022. doi: 10.1007/s10620-022-07494-9.

Barnes A, Krishnaprasad K, Carter D, Walsh A, Grafton R, Hughes J, Kaazan P, Cabaero A, Williams AJ, Ng W, Wierzbicki A, Connor SJ, Andrews JM. Novel IBD specific electronic medical record allows scalable auditing of IBD severity, therapy and complications to show the current unmet need in IBD care. Accepted Intestinal Research 24 March 2022. doi: 10.5217/ir.2022.00003

Gu B, Venkatesh K, Williams AJ, Ng W, Corte C, Gholamrezaei A, Ghaly S, Xuan W1,6, Paramsothy S, Connor SJ. Higher infliximab and adalimumab trough levels are associated with fistula healing in patients with fistulising perianal Crohn’s Disease. World J Gastroenterol 2022 June 21; 28(23): 2527-2635. doi: 10.3748/wjg.v28.i23.2597

Kanazaki R, Smith B, Girgis A, Descallar J, Connor SJ. Clinician adherence to inflammatory bowel disease guidelines: Results of a qualitative study of barriers and enablers. Accepted Crohn’s & Colitis 360 25 May 2022. doi: 10.1093/crocol/otac018

Barnes A, Ooi, S-Y J, Lynch KD, Parthasarathy N, Bishara M, Gounder M, Grafton R, Leach P, Bampton P, Sechi A, Ng W, Connor SJ, van Langenberg D, Mountifield R, Andrews JM. Proactive Metabolite Testing in Patients on Thiopurine May Yield Long‑Term Clinical Benefits in Inflammatory Bowel Disease. Dig Dis Sci. 10 June 2022. doi: 10.1007/s10620-022-07556-y

Liu Z, Julsgaard M, Zhu X, Martin J, Barclay ML, Cranswick N, Gibson PR, Gearry RB,van der Giessen J, Connor SJ, Rosella O, Grosen A, Toong C, Flanagan E, Wieringa JW, van der Woude CJ, Bell SJ. Timing of live attenuated vaccination in infants exposed to infliximab or adalimumab in utero: A prospective cohort study in 107 children. Journal of Crohn’s and Colitis December 2022: 16 (12):1835–1844. https://doi.org/10.1093/ecco-jcc/jjac093

Mortlock S, Lord A, Montgomery G, Zakrzewski M, Simms LA, Krishnaprasad K, Hanigan K, Doecke JD, Walsh A, Lawrance IC, Bampton PA, Andrews JM, Mahy G, Connor SJ, Sparrow MP, Bell S, Florin TH, Begun J, Gearry RB, Radford-Smith GL. An extremes of phenotype approach confirms significant genetic heterogeneity in patients with ulcerative colitis. Journal of Crohn's and Colitis. 16 September 2022: https://doi.org/10.1093/ecco-jcc/jjac121

Lores, T, Krishnaprasad K, Connor SJ, Cabaero A; Andrews MJ. Integration of mental health and quality of life screening tools in an Inflammatory Bowel Disease-specific electronic medical record (Crohn’s Colitis Care): Process and early outcomes. Internal Medicine Journal 24 January 2023. https://doi.org/10.1111/imj.15989

Mah C, Jayawardana C, Leong G, Koentgen S, Lemberg D, Connor SJ, Rokkas T, Grimm MC, Leach S, Hold GL. Assessing the relationship between the gut microbiota and inflammatory bowel disease therapeutics: A systematic review and meta-analysis. Pathogens 2023, 12(2), 262; https://doi.org/10.3390/pathogens12020262

Chan PPY, Farzin M, Acharya P, Viiala N, Gilmore A, Crane H Henderson C, Ng WS, Williams AJ, Connor SJ. Colonic Epstein-Barr Virus-Associated Mucocutaneous Ulcer Associated With Ulcerative Colitis. ACG Case Reports Journal 10(2):p e00978, February 2023. doi: 10.14309/crj.0000000000000978

Louis E, Resche-Rigon M, Laharie D, Satsangi J, Ding N, Siegmund B, D’Haens G, Picon L, Bossuyt P, Vuitton L, Irving P, Viennot S, Lamb CA, Pollok R, Baert F, Nachury M, Fumery M, Gilletta C, Almer S, Ben-Horin S, Bouhnik Y, Colombel JF, Hertervig E, GETAID and the SPARE-Biocycle Research Group. Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial. The Lancet Gastroenterology and Hepatology. March 2023: 8 (3): 215-227: https://doi.org/10.1016/S2468-1253(22)00385-5